Considering the recent approval of Amgen's Uplizna and overall positive market sentiment towards healthcare stocks, I anticipate an opportunity for a ...
Read
More
Considering the recent approval of Amgen's Uplizna and overall positive market sentiment towards healthcare stocks, I anticipate an opportunity for a short position on AMGN as its current valuation may not reflect potential market corrections prompted by broader economic uncertainties and competitive pressures.
Despite recent positive earnings and growth projections for Amgen, the company has underperformed and is currently trading near its 52-week low. I bel...
Read
More
Despite recent positive earnings and growth projections for Amgen, the company has underperformed and is currently trading near its 52-week low. I believe this presents a short opportunity, as market sentiment may not sustain the recent optimism despite the potential upside in the biotech sector.